Friday, July 10, 2026

pharma · Extensive-stage Small Cell Lung Cancer · Gastric Cancer

Shanghai Medical College

Fudan University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Extensive-stage Small Cell Lung Cancer, Gastric Cancer, Hodgkin Lymphoma, Cancer of Unknown Primary Site. NovaPharmaN

CN HQ
20 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
20
Programs
4
Drugs
3
Patents
0
Clinical program

tissue-of-origin (ORIGIN-PanCA○R) profiling

Phase 3 · gene therapy · Cancer of Unknown Primary Site

tissue-of-origin (ORIGIN-PanCA○R) profiling for Cancer of Unknown Primary Site is a Phase 3 program (gene_therapy) at Fudan University with 1 ClinicalTrials.gov record(s).

← All Fudan University projects Phase 3 gene therapy completed

Internal code Fudan CUP-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Fudan University
Phase
Phase 3
Modality
gene_therapy
Indication
Cancer of Unknown Primary Site
Status
completed
Trials
1

Clinical trials